Citations (70)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Gates B Colbert, Hector M Madariaga, Anna Gaddy, Mohamed E Elrggal & Edgar V Lerma. (2023) Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy. Therapeutics and Clinical Risk Management 19, pages 133-142.
Read now
Read now
Xu Jiang, Sungyeun Bae, Deok Yong Yoon, Shin Jung Park, Jaeseong Oh, Joo-Youn Cho & Kyung-Sang Yu. (2023) Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects. Drug Design, Development and Therapy 17, pages 2137-2145.
Read now
Read now
Claudia Stöllberger, Josef Finsterer & Birke Schneider. (2023) Adverse events and drug–drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure. Expert Review of Cardiovascular Therapy 21:11, pages 803-816.
Read now
Read now
Jeffrey Shi Kai Chan, Francesco Perone, Yasmin Bayatpoor, Gary Tse & Amer Harky. (2023) Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease. Expert Opinion on Pharmacotherapy 24:8, pages 935-945.
Read now
Read now
Nasir Shah, Vlado Perkovic & Sradha Kotwal. (2022) Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria. Expert Review of Clinical Pharmacology 15:7, pages 827-842.
Read now
Read now
André J. Scheen. (2022) Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties. Expert Opinion on Drug Metabolism & Toxicology 18:6, pages 381-393.
Read now
Read now
Taichi Minami, Akiko Kameda & Yasuo Terauchi. (2021) An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. Expert Opinion on Pharmacotherapy 22:16, pages 2087-2094.
Read now
Read now
Panagiotis-Nikolaos Lalagkas, Georgios Poulentzas, Christos Kontogiorgis & Antonios Douros. (2021) Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence. Expert Opinion on Drug Metabolism & Toxicology 17:6, pages 697-705.
Read now
Read now
Lakshini Y Herat, Vance B Matthews, Aaron L Magno, Marcio G Kiuchi, Revathy Carnagarin & Markus P Schlaich. (2020) An evaluation of empagliflozin and it’s applicability to hypertension as a therapeutic option. Expert Opinion on Pharmacotherapy 21:10, pages 1157-1166.
Read now
Read now
Ioannis Avgerinos, Aris Liakos, Apostolos Tsapas & Eleni Bekiari. (2019) Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Diabetes, Metabolic Syndrome and Obesity 12, pages 2549-2557.
Read now
Read now
Alvaro Garcia-Ropero, Carlos G. Santos-Gallego, M. Urooj Zafar & Juan J. Badimon. (2019) Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 15:4, pages 275-285.
Read now
Read now
Articles from other publishers (59)
Kyung Ah Han, Yong Hyun Kim, Doo Man Kim, Byung Wan Lee, Suk Chon, Tae Seo Sohn, In Kyung Jeong, Eun-Gyoung Hong, Jang Won Son, Jae Jin Nah, Hwa Rang Song, Seong In Cho, Seung-Ah Cho & Kun Ho Yoon. (2023) Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial. Diabetes & Metabolism Journal 47:6, pages 796-807.
Crossref
Crossref
Rahul Gupta, Theresa Maitz, David Egeler, Anila Mehta, Mark Nyaeme, Adrija Hajra, Akshay Goel, Jayakumar Sreenivasan, Neel Patel & Wilbert S. Aronow. (2023) SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure. Trends in Cardiovascular Medicine 33:8, pages 479-486.
Crossref
Crossref
Caroline R. Gross, Robin Varghese & Zdravka Zafirova. (2023) Perioperative Management of Novel Pharmacotherapies for Heart Failure and Pulmonary Hypertension. Anesthesiology Clinics.
Crossref
Crossref
Wei-Syun Hu & Cheng-Li Lin. (2023) Sodium-glucose cotransporter-2 inhibitor in risk of sepsis/septic shock among patients with type 2 diabetes mellitus—a retrospective analysis of nationwide medical claims data. Naunyn-Schmiedeberg's Archives of Pharmacology.
Crossref
Crossref
Francesca Mancinetti, Dionysios Xenos, Michelantonio De Fano, Alessio Mazzieri, Francesca Porcellati, Virginia Boccardi & Patrizia Mecocci. (2023) Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways. Ageing Research Reviews 90, pages 102018.
Crossref
Crossref
Haigang Cui, Xin Luo, Mingwei Chen, Jun Lu & Johnson J. Liu. (2023) Investigational Agents Targeting SGLT1 and SGLT2 in the Treatment of
Type 2 Diabetes Mellitus. Current Drug Targets 24:8, pages 648-661.
Crossref
Crossref
Hengli Zhao, Zhirui Zhao, Kun He, Nianrong Mi, Kai Lou, Xiaolin Dong, Wenyu Zhang, Jingfang Sun, Xinyu Hu, Shuguang Pang, Hong Cheng & Qing Wen. (2023) Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment. Clinical Pharmacokinetics 62:8, pages 1093-1103.
Crossref
Crossref
Wei-Syun Hu & Cheng-Li Lin. (2023) Psychiatric disorders in patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors—a nationwide retrospective cohort study. Naunyn-Schmiedeberg's Archives of Pharmacology.
Crossref
Crossref
Yu Zhang, Panpan Xie, Yamei Li, Zhixing Chen & Aixin Shi. (2023) Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches. Frontiers in Pharmacology 14.
Crossref
Crossref
Bela Patel, Lisa Pair & Michele Talley. (2023) Type 2 Diabetes: SGLT2i-Associated Genitourinary Infections and Lower Urinary Tract Dysfunction. The Journal for Nurse Practitioners 19:6, pages 104615.
Crossref
Crossref
Buena Aziri, Edin Begic, Slobodan Jankovic, Zorica Mladenovic, Bojan Stanetic, Tamara Kovacevic‐Preradovic, Amer Iglica & Aida Mujakovic. (2023) Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events. ESC Heart Failure 10:3, pages 1499-1530.
Crossref
Crossref
Keiko Unno, Kyoko Taguchi, Yoshiichi Takagi, Tadashi Hase, Shinichi Meguro & Yoriyuki Nakamura. (2023) Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption. International Journal of Molecular Sciences 24:7, pages 6278.
Crossref
Crossref
Panagiota Efstathia Nikolaou, Nikolaos Mylonas, Manousos Makridakis, Marina Makrecka-Kuka, Aikaterini Iliou, Stelios Zerikiotis, Panagiotis Efentakis, Stavros Kampoukos, Nikolaos Kostomitsopoulos, Reinis Vilskersts, Ignatios Ikonomidis, Vaia Lambadiari, Coert J. Zuurbier, Agnieszka Latosinska, Antonia Vlahou, George Dimitriadis, Efstathios K. Iliodromitis & Ioanna Andreadou. (2022) Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?. Basic Research in Cardiology 117:1.
Crossref
Crossref
RAVIKANTH INTURI, MEDEPALLI DAVID RAJU, MANDAVA VENKATA BASAVESWARA RAO & SRIKANTH INTURI. (2022) PHARMACOKINETIC INVESTIGATION OF REMOGLIFLOZIN IN RAT PLASMA SAMPLES BY HIGH-THROUGHPUT HPLC-MS-MS. International Journal of Applied Pharmaceutics, pages 178-185.
Crossref
Crossref
Alaa Mohamed Zaki, Dina Essam Abo-Elnour, Yomna Emad Abdalla, Rehab Yosri Hassan, Moaz Khaled Salama, Toka Elboraay & Ibrahim Abdelmonaem Abdelhaleem. (2022) Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:11, pages 102657.
Crossref
Crossref
Khyati Patel & Arun Nair. (2022) A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis. Cureus.
Crossref
Crossref
Jun Gi Hwang, SeungHwan Lee, Wan Huh, Jumi Han, Jaeseong Oh, In‐Jin Jang & Kyung‐Sang Yu. (2022) Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects. British Journal of Clinical Pharmacology 88:9, pages 4100-4110.
Crossref
Crossref
Shanqing He, Yajun Yao, Nan Yang, Youcheng Wang, Dishiwen Liu, Zhen Cao, Huiyu Chen, Yuntao Fu, Mei Yang, Songjun Wang, Guangjie He & Qingyan Zhao. (2022) Dapagliflozin Protects Methamphetamine-Induced Cardiomyopathy by Alleviating Mitochondrial Damage and Reducing Cardiac Function Decline in a Mouse Model. Frontiers in Pharmacology 13.
Crossref
Crossref
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa & Georgios Germanidis. (2022) The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications. Pharmacological Research 181, pages 106261.
Crossref
Crossref
Gauravpal S. Gill, Azka Latif, Daniel Hilleman, Carl J. Lavie & Venkata M. Alla. (2022) Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 Inhibitors and GLP-1 Analogs?. Current Problems in Cardiology 47:7, pages 100878.
Crossref
Crossref
Manuel Botana, Javier Escalada, Ángel Merchante, Rebeca Reyes & Pedro Rozas. (2022) Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review. Diabetes Therapy 13:S1, pages 5-17.
Crossref
Crossref
Gang Chen, Xiaolin Li, Quexuan Cui, Yangzhong Zhou, Bin Zhao, Dan Mei & Xuemei. (2022) Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study. International Urology and Nephrology 54:11, pages 2949-2957.
Crossref
Crossref
Xuefeng Chen, Qian Yang, Wenlou Bai, Wenjing Yao, Litian Liu, Yuanyuan Xing, Cunliang Meng, Peng Qi, Yi Dang & Xiaoyong Qi. (2022) Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF-β1/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure. Frontiers in Pharmacology 13.
Crossref
Crossref
Xiangning Cui, Jingwu Wang, Yang Zhang, Jianliang Wei & Yan Wang. (2022) Plin5, a New Target in Diabetic Cardiomyopathy. Oxidative Medicine and Cellular Longevity 2022, pages 1-20.
Crossref
Crossref
Jin-Woo Park, Jong-Min Kim, Ji Hyeon Noh, Kyoung-Ah Kim, Hyewon Chung, EunJi Kim, Minja Kang & Ji-Young Park. (2022) Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans. Pharmaceutics 14:3, pages 591.
Crossref
Crossref
Xueliang Wang, Zhe Wang, Di Liu, Hao Jiang, Chao Cai, Guoyun Li & Guangli Yu. (2022) Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease. Frontiers in Pharmacology 13.
Crossref
Crossref
Tetsuo Hayakawa, Ken-Ichiro Kato, Shinji Kobuchi, Kaede Kataoka & Toshiyuki Sakaeda. (2022) Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus. Pharmaceuticals 15:2, pages 203.
Crossref
Crossref
Minkook Son, Ye Sung Lee, A Ram Hong, Jee Hee Yoon, Hee Kyung Kim, Ho-Cheol Kang & Sung Yang. (2020) Improved Erythrocyte Deformability Induced by Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients. Cardiovascular Drugs and Therapy 36:1, pages 59-67.
Crossref
Crossref
Kevin S. ShahJames C. Fang. (2022) Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure. Annual Review of Pharmacology and Toxicology 62:1, pages 109-120.
Crossref
Crossref
Ebru Arioglu-Inan & Gizem Kayki-Mutlu. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
634
655
.
Armand A. Krikorian & Angela Pauline P. Calimag. 2022. Diabetes and Kidney Disease. Diabetes and Kidney Disease
443
467
.
Yuze Zhang, Xiaoyan Lin, Yong Chu, Xiaoming Chen, Heng Du, Hailin Zhang, Changsheng Xu, Hong Xie, Qinyun Ruan, Jinxiu Lin, Jie Liu, Jinzhang Zeng, Ke Ma & Dajun Chai. (2021) Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling. Cardiovascular Diabetology 20:1.
Crossref
Crossref
Kazuya Maeda, Akihiro Hisaka, Kiyomi Ito, Yoshiyuki Ohno, Akihiro Ishiguro, Reiko Sato & Naomi Nagai. (2021) Classification of drugs for evaluating drug interaction in drug development and clinical management. Drug Metabolism and Pharmacokinetics 41, pages 100414.
Crossref
Crossref
Jing Yu, Huanhuan Zhao, Xin Qi, Liping Wei, Zihao Li, Chunpeng Li, Xiaoying Zhang & Hao Wu. (2021) Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy. Frontiers in Pharmacology 12.
Crossref
Crossref
Jasna Klen & Vita Dolžan. (2021) Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations. International Journal of Molecular Sciences 22:18, pages 9800.
Crossref
Crossref
Natasha Srinivas, Mubashira K Sarnaik, Srimy Modi, Yasaswi Pisipati, Sarayoo Vaidya, Naqvi Syed Gaggatur, Aliya H Sange & Ibrahim Sange. (2021) Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus. Cureus.
Crossref
Crossref
Michele Provenzano, Maria Chiara Pelle, Isabella Zaffina, Bruno Tassone, Roberta Pujia, Marco Ricchio, Raffaele Serra, Angela Sciacqua, Ashour Michael, Michele Andreucci & Franco Arturi. (2021) Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge. Frontiers in Medicine 8.
Crossref
Crossref
Carlos G. Santos-Gallego, Juan Antonio Requena-Ibanez, Rodolfo San Antonio, Alvaro Garcia-Ropero, Kiyotake Ishikawa, Shin Watanabe, Belen Picatoste, Ariana P. Vargas-Delgado, Eduardo J. Flores-Umanzor, Javier Sanz, Valentin Fuster & Juan J. Badimon. (2021) Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure. JACC: Cardiovascular Imaging 14:2, pages 393-407.
Crossref
Crossref
Алла Алексеевна Колесникова, Олег Леонидович Колесников & Юлия Олеговна Тарабрина. (2021) О влиянии ингибиторов натрий-глюкозного котранспортера 2 на состояние митохондрий и активность аутофагии. Естественные и Технические Науки:№09, pages 125-129.
Crossref
Crossref
Yue Wang, Ran Bi, Fei Quan, Qiuhua Cao, Yanting Lin, Chongxiu Yue, Xinmeng Cui, Hongbao Yang, Xinghua Gao & Dayong Zhang. (2020) Ferroptosis involves in renal tubular cell death in diabetic nephropathy. European Journal of Pharmacology 888, pages 173574.
Crossref
Crossref
S. R. Tittel, K. M. Sondern, M. Weyer, T. Poeplau, B. M. Sauer, M. Schebek, K.-H. Ludwig, F. Hammer, E. Fröhlich-Reiterer & R. W. Holl. (2020) Multicentre analysis of hyperglycaemic hyperosmolar state and diabetic ketoacidosis in type 1 and type 2 diabetes. Acta Diabetologica 57:10, pages 1245-1253.
Crossref
Crossref
Ju-Hyun Kim, Dong Kyun Kim, Won-Gu Choi, Hye-Young Ji, Ji-Soo Choi, Im-Sook Song, Sangkyu Lee & Hye Suk Lee. (2020) In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes. Pharmaceutics 12:9, pages 865.
Crossref
Crossref
André J. Scheen. (2020) Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease. Clinical Pharmacokinetics 59:8, pages 981-994.
Crossref
Crossref
Daryl J. Fediuk, Gianluca Nucci, Vikas Kumar Dawra, David L. Cutler, Neeta B. Amin, Steven G. Terra, Rebecca A. Boyd, Rajesh Krishna & Vaishali Sahasrabudhe. (2020) Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. Clinical Pharmacokinetics 59:8, pages 949-965.
Crossref
Crossref
Cesar A. Martinez & Claudio Scafoglio. (2020) Heterogeneity of Glucose Transport in Lung Cancer. Biomolecules 10:6, pages 868.
Crossref
Crossref
Kristien E. C. Bouter, Erik J. M. van Bommel, Hans Jansen, Dewi van Harskamp, Henk Schierbeek, Mariëtte T. Ackermans, Mireille J. Serlie, Alinda W. M. Schimmel, Max Nieuwdorp, Geesje M. Dallinga‐Thie & Daniël H. van Raalte. (2020) The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well‐controlled plasma LDL cholesterol. Diabetes, Obesity and Metabolism 22:6, pages 988-996.
Crossref
Crossref
Hong Zhang, Jingrui Liu, Xiaoxue Zhu, Xiaojiao Li, Hong Chen, Min Wu, Cuiyun Li & Yanhua Ding. (2020) A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State. Clinical Therapeutics 42:5, pages 892-905.e3.
Crossref
Crossref
Shashank Joshi, Girish Gudi, Vinu C. A. Menon, Monika Tandon, Vikas Joshi, Sachin Suryawanshi, Hanmant Barkate, Nikhil Sawant, Sagar Katare & Waseem Siddique. (2019) An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions. Clinical Pharmacokinetics 59:3, pages 349-357.
Crossref
Crossref
Hong Zhang, Xiaoxue Zhu, Xiaojiao Li, Hong Chen, Min Wu, Cuiyun Li, Jingrui Liu, Chengjiao Liu, Yingjun Zhang & Yanhua Ding. (2019) Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 22:2, pages 191-202.
Crossref
Crossref
Orly Vardeny. (2020) The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors. The American Journal of Medicine 133:2, pages 182-185.
Crossref
Crossref
M. A. de Laat & M. N. Sillence. (2020) A review of recent developments in the pharmacological prevention and treatment of endocrinopathic laminitis. Animal Production Science 60:18, pages 2111.
Crossref
Crossref
Nannan Zhang, Bin Feng, Xuexing Ma, Kangyun Sun, Guidong Xu & Yafeng Zhou. (2019) Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Emily J. North & Jonathan D. Newman. (2019) Review of cardiovascular outcomes trials of sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Current Opinion in Cardiology 34:6, pages 687-692.
Crossref
Crossref
Alvaro Garcia-Ropero, Carlos G Santos-Gallego & Juan J Badimon. (2019) SGLT receptors and myocardial ischaemia-reperfusion injury: inhibition of SGLT-1, SGLT-2, or both?. Cardiovascular Research 115:11, pages 1572-1573.
Crossref
Crossref
Álvaro García-Ropero, Carlos G Santos-Gallego & Juan J. Badimon. (2019) The anti-inflammatory effects of SGLT inhibitors. Aging 11:16, pages 5866-5867.
Crossref
Crossref
Álvaro García-Ropero, Ariana P. Vargas-Delgado, Carlos G. Santos-Gallego & Juan J. Badimon. (2019) Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance. International Journal of Molecular Sciences 20:13, pages 3289.
Crossref
Crossref
Md. Mahbubur Rahman Bhuiyan & Anawara Begum. (2019) Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018. Obesity Medicine 14, pages 100099.
Crossref
Crossref
Carlos G. Santos-Gallego, Alvaro Garcia-Ropero, Donna Mancini, Sean P. Pinney, Johanna P. Contreras, Icilma Fergus, Vivian Abascal, Pedro Moreno, Farah Atallah-Lajam, Ronald Tamler, Anu Lala, Javier Sanz, Valentin Fuster & Juan Jose Badimon. (2019) Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?. Cardiovascular Drugs and Therapy 33:1, pages 87-95.
Crossref
Crossref
Yuka Kamijo, Hideto Ishii, Tomohiko Yamamoto, Kunihisa Kobayashi, Hiroyuki Asano, Shunji Miake, Eiichiro Kanda, Hidenori Urata & Masayuki Yoshida. (2019) Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes. Clinical Medicine Insights: Endocrinology and Diabetes 12, pages 117955141986681.
Crossref
Crossref